SCHEMBL20420788

SCHEMBL20420788

COc1ccc(-c2ccc(-c3cc(=O)oc4ccccc34)o2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.61
▸ KDM4E B2RXH2 7/20 0.61
▸ HPGD P15428 6/20 0.61
▸ MAPT P10636 4/20 0.61
▸ MAOB P27338 3/20 0.61
▸ RAB9A P51151 3/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ LMNA P02545 3/20 0.61
▸ CYP3A4 P08684 3/20 0.61
▸ HSD17B10 Q99714 3/20 0.61
▸ NPC1 O15118 2/20 0.61
▸ TP53 P04637 2/20 0.61
▸ THRB P10828 2/20 0.61
▸ TNKS O95271 1/20 0.61
▸ GLA P06280 1/20 0.61
▸ KCNA5 P22460 1/20 0.61
▸ KCNH2 Q12809 1/20 0.61
▸ NLRP3 Q96P20 1/20 0.61
▸ KMT2A Q03164 1/20 0.57
▸ NOD2 Q9HC29 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13236780 0.88 NOD2 (0.68) ALDH1A1KDM4EHPGDMAPTMAOB
SCHEMBL20420761 0.85 MAOB (0.58) ALDH1A1KDM4EHPGDMAPTMAOB
SCHEMBL20420777 0.84 CA9 (0.54) HPGDMAOBRAB9ASMN1; SMN2CYP3A4
SCHEMBL20420727 0.82 TNKS (0.58) HPGDMAOBRAB9ASMN1; SMN2CYP3A4
SCHEMBL20420775 0.82 PTGES (0.53) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL20420733 0.82 MAOB (0.64) ALDH1A1KDM4EHPGDMAPTMAOB
SCHEMBL20428325 0.82 HPGD (0.61) ALDH1A1KDM4EHPGDMAPTMAOB
SCHEMBL20420716 0.81 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDMAPTRAB9A
SCHEMBL20428422 0.81 NQO1 (0.49) ALDH1A1KDM4EHPGDMAPTMAOB
SCHEMBL20420725 0.81 NOD2 (0.54) ALDH1A1KDM4EHPGDMAPTMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3354648-B1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF CHENGDU ZENITAR BIOMEDICAL TECH CO LTD (CN) 2022-04-06 — — EP disclosed
CN-108349959-B 4-substituted coumarin derivative and preparation method and application thereof 成都赜灵生物医药科技有限公司 2021-11-16 — — CN disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 — — US disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 — — US disclosed
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) 2018-10-04 — — US disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 — — EP disclosed
EP-3354648-A1 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) 2018-08-01 — — EP disclosed
CN-108349959-A The coumarin derivative and its preparation method and application of 4 substitutions 贵州百灵企业集团制药股份有限公司 2018-07-31 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof MAP4, TUBA3C, ABCC1 ALDH1A1 725/4885KDM4E 1307/4885HPGD 2933/4885
US-20180282315-A1 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF MAP4, TUBA3C, ABCC1 ALDH1A1 725/4885KDM4E 1307/4885HPGD 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback